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Obesity and metabolic syndrome are associated
with an increased risk for lipotoxic cardiomyopathy,
which is strongly correlated with excessive accumu-
lation of lipids in the heart. Obesity- and type-2-dia-
betes-related disorders have been linked to altered
expression of the transcriptional cofactor PGC-1a,
which regulates the expression of genes involved
in energy metabolism. Using Drosophila, we identify
PGC-1/spargel (PGC-1/srl) as a key antagonist of
high-fat diet (HFD)-induced lipotoxic cardiomyopa-
thy. We find that HFD-induced lipid accumulation
and cardiac dysfunction are mimicked by reduced
PGC-1/srl function and reversed by PGC-1/srl over-
expression. Moreover, HFD feeding lowers PGC-1/
srl expression by elevating TOR signaling and in-
hibiting expression of the Drosophila adipocyte tri-
glyceride lipase (ATGL) (Brummer), both of which
function as upstream modulators of PGC-1/srl. The
lipogenic transcription factor SREBP also contrib-
utes to HFD-induced cardiac lipotoxicity, likely in
parallel with PGC-1/srl. These results suggest a
regulatory network of key metabolic genes that
modulates lipotoxic heart dysfunction.
INTRODUCTION
Heart failure is a major cause of mortality in modern society. The
high prevalence of obesity and related diseases, including type 2
diabetes, plays a significant role in the increased incidence of
cardiovascular disease, which affects more than a billion people
worldwide. It is now recognized that obesity and diabetes are
associated with lipotoxic cardiomyopathy, a form of cardiac
dysfunction that is caused by excessive lipid accumulation in
myocardial cells (Borradaile and Schaffer, 2005; Christoffersen
et al., 2003). The high incidence of obesity-associated heart
dysfunction is aggravated by changes in nutritional habits,
such as consumption of high-caloric diets, combined with
reduced physical activity. A major challenge in developing tar-
geted therapeutics for this type of heart disease is to understand1572 Cell Reports 10, 1572–1584, March 10, 2015 ª2015 The Authorhow the molecular and genetic changes induced by high-caloric
diets lead to metabolic imbalances that culminate in cardiac
dysfunction.
Although mammalian model organisms are ultimately essen-
tial for identifying the underlying mechanisms of obesity and
metabolic syndrome (Kanasaki and Koya, 2011; York and Bou-
chard, 2000), the genetic and metabolic complexity and gene
redundancy in higher organisms complicates dissection of the
fundamental genetic relationships involved in these diseases.
However, the components and regulatory pathways of core
metabolic pathways are generally highly conserved, making
genetically simpler invertebrate models, such as Drosophila,
well suited for such studies (Baker and Thummel, 2007; Botstein
et al., 1997; Broughton et al., 2005; Diop and Bodmer, 2012;
Ku¨hnlein, 2012; Noyes et al., 1995). Drosophila is unique in that
it is the only invertebrate model organism with a beating heart
for which suitable genetic tools and assays are available to study
heart function (Bier and Bodmer, 2004; Ocorr et al., 2007, 2014;
Wessells et al., 2004; Wolf et al., 2006).
Recent studies with Drosophila models of obesity-associated
heart dysfunction have demonstrated that consumption of high-
fat or -sugar diets, or genetic manipulation of key metabolic reg-
ulators, can lead to excessive fat accumulation accompanied
by severe heart defects, including increased frequency of ar-
rhythmias, reduced cardiac output, increased non-contractile
myocardial cells, and altered myofibrillar structure and collagen
content (Birse et al., 2010; Diop and Bodmer, 2012; Lee et al.,
2010; Lim et al., 2011; Na et al., 2013). Thus, flies challenged
with high-caloric diets display metabolic responses and
increased risk for heart disease reminiscent of those observed
in humans. Importantly, these studies showed that inhibition of
signaling through insulin, target of rapamycin (TOR), or the lipo-
genic transcription factor SREBP or by increasing triacylglycer-
ide (TAG) lipolysis were effective in counteracting excess lipid
accumulation as well as the associated cardiac defects.
Although these findings suggested that major metabolic path-
ways could be targeted for therapeutic intervention in human
obesity-induced cardiomyopathy, further work is necessary to
obtain a more-complete understanding of the essential regula-
tors of these lipogenic pathways and their relationship to cardiac
function. In this study, we use the Drosophilamodel to delineate
novel genetic relationships between key metabolic regulators
relevant to cardiac lipotoxicity.s
Peroxisome proliferator-activated receptor g (PPARg) coacti-
vator-1 (PGC-1) is a transcriptional coactivator first identified as
a key regulator of thermogenesis in brown adipose tissue in
mammals (Puigserver et al., 1998). Subsequently, additional
PGC-1 family members have been shown to modulate gene
expression by interacting with a number of nuclear receptors
(Finck and Kelly, 2006; Gleyzer and Scarpulla, 2011; Lin et al.,
2002). Studies in mice and flies have demonstrated that PGC-1
proteins are induced by environmental stimuli, such as cold
exposure, exercise, or starvation, triggering a number of meta-
bolic adaptations (Arany, 2008; Baar et al., 2002; Goto et al.,
2000; LeMoine et al., 2008; Tiefenbo¨ck et al., 2010; Tinkerhess
et al., 2012; Zechner et al., 2010). PGC-1a is the most-studied
member of the PGC-1 family and plays key roles inmitochondrial
biogenesis and electron transport chain assembly by interacting
with nuclear respiratory factor (NRF) and estrogen-related re-
ceptor (ERR) transcription factors (Rowe et al., 2010; Russell
et al., 2004; Scarpulla, 2011; Tiefenbo¨ck et al., 2010). PGC-1a
also controls mitochondrial fatty acid oxidation in the muscles
and liver by coactivating members of the PPAR and retinoic X re-
ceptor families of nuclear factors (Vega et al., 2000; Zechner
et al., 2010). The PGC-1a/ERR axis has also been implicated in
controlling cardiac metabolism and function (Finck and Kelly,
2006, 2007; Lai et al., 2008; Patten and Arany, 2012; Schilling
and Kelly, 2011). Interestingly, decreased cardiac PGC-1a
expression, observed in adipocyte triglyceride lipase (ATGL)-
deficient mice, is associated with cardiac lipid accumulation
and subsequent heart failure (Haemmerle et al., 2011). Of note,
sequence variation at the PGC-1a locus has been correlated
with obesity in humans (Rankinen et al., 2006). Despite the
known involvement of PGC-1 in cardiac function, it is still unclear
whether or how PGC-1 protein interacts with other metabolic
regulators and signaling pathways in modulating the deleterious
effects of high-caloric diets on lipid accumulation and cardiomy-
opathy. In particular, it is not known whether TOR and SREBP
pathways interact with PGC-1/spargel (PGC-1/srl) function in
these processes.
In this study, we provide evidence that reducing the function of
Drosophila PGC-1/srl causes a phenotype of excess fat accu-
mulation and severe heart dysfunction that is remarkably similar
to that observed in wild-type flies exposed to a high-fat diet
(HFD). This phenotype is exacerbated in PGC-1/srl mutant
flies that are fed a HFD, whereas systemic or cardiac-specific
PGC-1/srl overexpression is protective. Genetic interaction ex-
periments suggest that PGC-1/srl is likely to act downstream
of TOR signaling to protect the heart from lipotoxicity. We
show that the protective effect of reduced TOR signaling re-
quires elevated expression of PGC-1/srl and ATGL (major TAG
lipase encoded by brummer [bmm] in Drosophila), with ATGL/
bmm positioned downstream of TOR and upstream of PGC-1/
srl in the homeostatic control of fat accumulation and cardiac lip-
otoxicity. Interestingly, these PGC-1/srl manipulations did not
change the expression or processing of SREBP and reducing
SREBP does not significantly ameliorate heart dysfunction of
PGC-1/srl heterozygotes, suggesting that PGC-1/srl and SREBP
do not act in a strict epistatic relationship. Taken together, our
data define a new interaction network of key metabolic regula-
tors that contribute to cardiac lipotoxicity in Drosophila andCellthus provide insights into possible mechanisms of HFD-associ-
ated cardiomyopathy relevant to humans.
RESULTS
HFD-Induced Fat Accumulation Requires Reduced
PGC-1/srl Expression
To determine the involvement of Drosophila PGC-1/srl in obesity
and heart dysfunction, we first examined the effect of PGC-1/srl
modulation on whole-body triglyceride (TAG) content in wild-
type (w1118) flies, heterozygous PGC-1/srl mutants (PGC-1XP/+
and PGC-1PBAC/+), and flies with systemic RNAi-mediated
PGC-1/srl knockdown (KD). Flies were raised on normal food
(NF) for 5–10 days and then transferred for a further 5 days to
NF or HFD (NF supplemented with 30% coconut oil). We found
that flieswith reducedPGC-1/srl functionhadelevatedTAG levels
compared with wild-type flies, and TAG levels were further
increased when the mutant or systemic PGC-1/srl KD flies
(arm > PGC-1RNAi) were fed a HFD (Figures 1A, 1B, and S1A).
Moreover, TAG levels were increased in the heart and muscle-
rich thorax of HFD-fed or PGC-1/srl heterozygous flies (Figures
1C and S1B), consistent with the deposition of TAG in additional
organs once the capacity of adipose tissue was exceeded. To
furtherdemonstrate that the increasedTAG level inPGC-1/srlhet-
erozygous mutant flies was specific to reduced PGC-1/srl func-
tion, we used a genomic rescue construct (PGC-1GR; Tiefenbo¨ck
et al., 2010) in flies carrying the PGC-1XPmutation.We found that
these flies (PGC-1XP/PGC-1GR) have a significantly lower TAG
level compared to PGC-1 heterozygous flies (PGC-1XP/+) under
NF or HFD (Figure 1A). These experiments show that a genomic
PGC-1/srl transgene was able to rescue the TAG phenotype of
thePGC-1/srlmutant flies in support of the idea that the observed
phenotype is specific to loss of PGC-1/srl function. The rescue
flies showa somewhat lower TAG level than thewild-type control,
which possibly reflects a slightly higher activity by the rescue
transgene compared to thewild-type allele.PGC-1/srlKD specif-
ically in adipose tissue (using the lsp-Gal4 driver) or muscle (24B-
Gal4 driver) also resulted in systemic fat accumulation in bothNF-
and HFD-fed flies, supporting an association between reduced
PGC-1/srl function and fat accumulation (Figures S1C and S1I).
Because wild-type flies on a HFD and flies with reduced PGC-
1/srl function on NF had similar levels of TAG, we asked whether
PGC-1/srl expression was modulated by HFD feeding. Indeed,
qPCR analysis showed that HFD decreased PGC-1/srl mRNA
in various tissues to a level comparable to PGC-1/srl heterozy-
gotes, including in the abdomen, the heart, and muscle-rich tho-
rax (Figures 1D–1F, S1D, and S1H). Conversely, TAG levels were
decreased in HFD-fed flies overexpressing PGC-1/srl systemi-
cally (Figures 1G, S1G, and S1J) or specifically in muscle (Fig-
ure S1E) or adipose tissue (Figure S1F). These findings suggest
that the HFD-induced reduction in PGC-1/srl function promotes
fat accumulation, whereas overexpression of PGC-1/srl blunts
the effect.
To further analyze the effects of HFD and reduced PGC-1/srl
function on lipid accumulation, we visualized lipid droplets in
cardiomyocytes by Nile Red staining. We observed an increase
in droplet size and fat content (Figure 1H) in the hearts of wild-
type flies on HFD and PGC-1/srl heterozygotes on NF or HFD.Reports 10, 1572–1584, March 10, 2015 ª2015 The Authors 1573
Figure 1. HFD-Induced Obesity Is Accom-
panied by a Reduction in PGC-1/srl
Function
(A) TAG content of PGC-1/srl mutant flies. Flies
were fed for 5–10 days on normal food (NF) and
then transferred to NF or HFD (NF + 30% coconut
oil) for a further 5 days. The wild-type (wt) strain is
w1118. PGC-1XP/+ and PGC-1GR are, respectively,
PGC-1 heterozygous mutant and PGC-1GR de-
notes flies that carry a wild-type PGC-1 genomic
rescue transgene. Results are expressed as the
fold difference in whole-fly TAG compared with
wild-type NF (WT-NF) flies and are the mean ±
SEM of n = at least 27 for all genotypes and con-
ditions (wt-NF replicates were normalized to their
average, thus contain error bars here and
throughout). **p < 0.01; ***p < 0.001; ****p <
0.0001; one-way ANOVA test.
(B) TAG content of PGC-1 knockdown flies.
Controls (KK control lines used to make PGC-1
RNAi) are the same genetic background as the
PGC-1RNAi line. Results are expressed as the fold
difference in whole-fly TAG compared with arm >
control-NF flies and are the mean ± SEM of 42% n
R 27. **p < 0.01; one-way ANOVA test.
(C) TAG content in the hearts of PGC-1/srlmutant
flies. Results are expressed as the fold difference
compared with WT-NF flies and are the mean ±
SEM of 250 % n R 200. **p < 0.01; one-way
ANOVA test.
(D–F) Relative PGC-1 mRNA levels in WT or PGC-
1/srlmutant flies. PGC-1mRNA was measured by
qPCR in (D) the abdomen of WT and PGC-1XP/+
heterozygous flies and (E) the abdomen or (F) the
heart of WT flies on NF or HFD. Results are
expressed as the fold difference compared with
WT flies and are the mean ± SEM of triplicates.
*p < 0.05; **p < 0.01; ANOVA and Student’s t tests.
(G) TAG content of flies overexpressing PGC-1/srl.
Results are expressed as the fold difference in
whole-fly TAG compared with arm/wt-NF flies and
are the mean ± SEM of 36 % n R 27. *p < 0.05;
one-way ANOVA test.
(H) Representative images of Nile Red staining
of lipid droplets in cardiomyocytes of WT and
PGC-1XP/+ flies onNF or HFD. Arrows indicate lipid
droplets; cardiomyocyte nuclei are stained green
by DAPI. See also Figure S1.HFD-Induced Reduction in PGC-1/srl Expression
Provokes Cardiac Lipotoxicity
The finding that PGC-1/srl heterozygotes and HFD-fed wild-type
flies accumulated fat in the heart (Figures 1C and 1H), together
with the reported link between obesity and heart disease in
humans and other mammals (Borradaile and Schaffer, 2005;
Zhou et al., 2000), prompted us to investigate the effect of
PGC-1/srl manipulation on heart function in Drosophila. For
this, we used the previously established methods of semi-intact
heart preparation, high-speed video recording, and SOHA soft-
ware analysis (Ocorr et al., 2007, 2009; Fink et al., 2009). We
observed that wild-type flies on HFD and flies with reduced
PGC-1/srl function on either NF or a HFD showed decreased
heart period (Figures 2A, 2B, and 2D; Movies S1, S2, S3, and
S4) due to reductions in both diastolic and systolic intervals (Fig-1574 Cell Reports 10, 1572–1584, March 10, 2015 ª2015 The Authorures S2A, S2B, S2D, and S2E). This is also illustrated in M-mode
traces (Figures 2D and 2E). Conversely, systemic PGC-1/srl
overexpression increased the heart period even under HFD con-
ditions (PGC-1EP flies; Figures 2C and 2E), which was primarily
due to an increased diastolic interval (Figures S2C and S2F).
Wild-type flies on HFD also showed reduced fractional short-
ening (Figures S2G and S2H), as previously noted (Birse et al.,
2010), but this parameter was unaffected by reduced PGC-1/
srl function (Figures S2G and S2H).
PGC-1/srl heterozygotes exhibited striking defects in other
aspects of cardiac contraction that were remarkably similar to
those observed upon HFD feeding. The defects included heart
tubes with regions lacking active contractions (‘‘non-contrac-
tile’’), asynchronous anterior versus posterior beating patterns
(‘‘asynchronous beating’’), dysfunctional inflow valves (ostia),s
Figure 2. HFD-Induced Cardiac Dysfunc-
tion Is Modulated by PGC-1/srl Function
(A) Heart periods of WT and PGC-1 heterozygous
flies. Results are the mean ± SEM of 45% nR 33.
*p < 0.05; **p < 0.01; one-way ANOVA test.
(B) Heart periods of control and PGC-1 knock-
down flies. Results are expressed as the mean ±
SEM of 22% nR 20. *p < 0.05; **p < 0.01; ***p <
0.001; one-way ANOVA test.
(C) Heart periods of control and PGC-1-over-
expressing flies. Results are the mean ± SEM of
32 % n R 16. *p < 0.05; ***p < 0.001; one-way
ANOVA test.
(D and E) Representative M-modes traces (5 s)
showing heart wall movements (y axis) versus
time (x axis). Stills are from high-speed movies
of semi-intact fly heart preparations for (D)
WT and PGC-1XP/+ flies on NF or HFD and (E)
PGC-1 knockdown (arm > PGC-1RNAi) and
PGC-1-overexpressing (arm > PGC-1EP) flies on
NF or HFD.
(F) Graphical representation of the proportion
of PGC-1/srl mutant, RNAi, and overexpression
flies displaying heart dysfunction phenotypes,
classified as non-contractile regions, asynchro-
nous beating, and other defects (dysfunctional
ostia, narrowed heart regions, and transmission
defects).
(G) Quantification of heart defects shown in (F).
Statistical significance was determined using chi-
square test 33% nR 14. WT-NF versus WT-HFD;
c2 = 15; p < 0.001. WT-HFD versus PGC-1XP/+-NF;
c2 = 0.008; ns. PGC-1XP/+-NF versus PGC-1XP/
PGC-1GR-NF; c2 = 15.78; p < 0.001. PGC-1XP/+-
HFD versus PGC-1XP/PGC-1GR-HFD; c2 = 23.00;
p < 0.001.WT-NF versus PGC-1XP/PGC-1GR-HFD;
c2 = 0.002; ns. GMH5/wt-NF versus GMH5 >
PGC-1RNAi1-NF; c2 = 7.03; p < 0.01. GMH5/wt-
HFD versus GMH5 > PGC-1RNAi2-HFD; c2 = 4.33;
p < 0.05. GMH5 > PGC-1RNAi2-NF versus
GMH5 > PGC-1RNAi1-NF; c2 = 0.17; ns. GMH5 >
PGC-1RNAi2-HFD versus GMH5 > PGC-1RNAi1-
HFD; c2 = 2.30; ns. GMH5/wt-NF versus GMH5 >
PGC-1EP-HFD; c2 = 0.13; ns. ns, not significant.
See also Figure S2 and Movies S1, S2, S3, S4, S5,
S6, and S7.and occasional localized constriction (‘‘other defects’’; Movies
S5, S6, and S7). Quantification of these parameters revealed
that cardiac dysfunction was markedly increased in wild-type
flies fed a HFD and in flies with reduced PGC-1/srl function
(PGC-1xp/+) and was further increased in PGC-1xp/+ flies on a
HFD (Figures 2F and 2G). Remarkably, PGC-1/srl heterozygous
flies containing a genomic PGC-1/srl transgene (PGC-1XP/
PGC-1GR) showed a significant decrease in cardiac dysfunction
under NF and HFD (Figures 2F and 2G), suggesting that adding a
genomic copy of PGC-1/srl to PGC-1/srl heterozygotes also
rescued the heart phenotypes. These data therefore suggested
that the HFD-induced reduction in PGC-1/srl function is associ-
ated not only with fat accumulation but also with HFD-induced
heart dysfunction.
To determine whether cardiac-specific KD of PGC-1/srl was
sufficient to cause heart dysfunction, we expressed two differentCellPGC-1/srl RNAi constructs using a cardiomyocyte-specific
driver (GMH5). Indeed, flies with PGC-1/srl KD exhibited pro-
nounced heart defects comparable to those observed in
PGC-1/srl heterozygotes or wild-type flies fed a HFD (Figures
2F and 2G), indicating that reducing PGC-1/srl function in the
heart alone was sufficient to cause dysfunction. The heart de-
fects tended to be more severe when cardiac PGC-1/srl KD flies
were exposed to a HFD, whereas HFD-fed flies with cardiac
overexpression of PGC-1/srl (PGC-1EP) showed a much-lower
incidence of heart defects (Figures 2F and 2G). These data
suggest that high levels of PGC-1/srl protected the heart from
HFD-induced dysfunction in a cardiac-autonomous fashion.
Conversely, downregulation of PGC-1/srl activity correlated
with the deleterious effects of HFD on cardiac function, although
it cannot be ruled out that reduced PGC-1/srl function also has
effects on the heart not related to fat accumulation.Reports 10, 1572–1584, March 10, 2015 ª2015 The Authors 1575
Figure 3. TOR Is an Upstream Regulator of PGC-1/srl and bmm in HFD-Induced Heart Dysfunction
(A) Western blots of phospho-AKT and phospho-S6K from WT and PGC-1/srl heterozygous flies on NF and HFD. Actin was used as loading control.
(B and C) Quantification of relative P (S6K) and P (AKT) protein based on densitometry measurements. Statistics were done using the Kruskal-Wallis test. **p <
0.05; ***p < 0.001. The data are presented as the mean ± SEM.
(D and E) Relative PGC-1/srl (D) and bmm (E) mRNA levels inWT and TORmutant on NF and HFD. Results are expressed as the fold difference comparedwithWT
flies. *p < 0.05; one-way ANOVA test. The data are presented as the mean ± SEM.
(legend continued on next page)
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Inhibition of TORActivity Elevates PGC-1/srl Expression
and Protects against HFD-Induced Heart Dysfunction
We previously showed that reduced TOR signaling can protect
against HFD-induced obesity and heart dysfunction in
Drosophila (Birse et al., 2010). Here, we find that HFD feeding
of wild-type flies activated TOR signaling, as shown by increased
levels of the phosphorylated (i.e., active) forms of AKT
(P-AKTS505) and S6K (P-S6KT398; Figures 3A–3C). These ob-
servations are consistent with the previously demonstrated pro-
tective effect of reduced TOR activity in lipotoxic heart dysfunc-
tion (Birse et al., 2010). To determine whether PGC-1/srl and
TOR might function through a common pathway, we examined
activation of AKT (upstream regulator of TOR) and S6K (down-
stream effector of TOR) in PGC-1/srl heterozygotes. Like wild-
type flies fed HFD, PGC-1 heterozygotes flies show an increase
of P-AKTS505 and P-S6KT398 under HFD; however, P-AKT and
P-S6K levels did not appear to be altered differently in PGC-1/srl
heterozygous flies compared to wild-type (Figures 3A–3C), sug-
gesting that PGC-1/srl was unlikely to be an upstream regulator
of TOR signaling in this situation.
We next asked whether manipulation of TOR signaling
affected PGC-1/srl expression. Indeed, NF-fed flies with
reduced TOR signaling (TOR7/P, previously shown to protect
from HFD-induced heart dysfunction; Birse et al., 2010) had
significantly increased PGC-1/srl mRNA levels (Figure 3D),
as did flies with systemic expression of dominant-negative
S6K (S6KDN; Figure S3B). Remarkably, the HFD-induced
reduction in PGC-1/srl mRNA level was reversed in TOR7/P
mutants (Figure 3D). These data therefore suggested that
reducing PGC-1/srl expression in TOR7/P mutants might
reduce or abrogate the protective effect of reduced TOR
signaling on HFD-induced fat accumulation. To test this, we
created flies with reduced function of both TOR and PGC-1/
srl (TOR7/P;PGC-1xp/+). In keeping with our hypothesis, the
double-mutant flies had elevated levels of TAG, similar to
those in PGC-1XP/+ flies, and TAG levels were further increased
upon HFD feeding (Figure 3F).
Next, we tested whether PGC-1/srl may also function down-
stream of TOR with regards to heart function. Indeed, we found
a high incidence of heart dysfunction in TOR7/P;PGC-1xp/+ dou-
ble-mutant flies, similar to that observed for single PGC-1XP/+
mutants (Figures 3G and 3H). These data suggested an epistatic
relationship between PGC-1/srl and TOR, in which TOR acted as
a negative upstream regulator of PGC-1/srl function in control-
ling fat content and heart function (Figure 3I). The findings further
suggested that the previously demonstrated cardioprotective
effect of reduced TOR signaling may require upregulation of
PGC-1/srl expression.(F) Relative TAG content in PGC-1/srl, bmm, and TOR single- and double-mutant
TAG compared with WT-NF flies and are the mean ± SEM of 66% nR 18. **p <
(G) Graphical representation of the proportion ofPGC-1/sr, bmm, and TOR single-
non-contractile regions, asynchronous beating, and other defects (dysfunctional
(H) Quantification of heart defects shown in (G). Statistical significance was determ
0.001.WT-HFD versus TOR7/P-HFD; c2 = 19.33; p < 0.001. PGC-1XP/+-HFD vers
HFD; c2 = 23.58; p < 0.001.WT-HFD versus TOR7/P; PGC-1XP/+-HFD; c2 = 0.46; n
1XP/+-HFD versus TOR7/P; bmm1/+-HFD; c2 = 0.01; ns. Bmm1/+-NF versus TOR
(I) Schematic of proposed regulatory network. HFD feeding activates TOR signali
and heart dysfunction. See also Figure S3.
CellThe ATGL/Bmm Lipase Acts Downstream of TOR and
Upstream of PGC-1/srl in Modulating HFD-Induced
Heart Dysfunction
Lipolysis, which is the process by which triglycerides are
degraded into free fatty acids, is a major component of lipid
metabolism. bmm, which encodes the Drosophila homolog of
mammalian ATGL lipase, also mediates fat hydrolysis in this
invertebrate model system (Gro¨nke et al., 2005). We previously
showed that bmm overexpression efficiently prevented HFD-
induced fat accumulation and heart dysfunction (Birse et al.,
2010). Therefore, we asked how Bmm might contribute to the
TOR- and PGC-1-regulated effects on lipid accumulation and
cardiac function. Interestingly, the phenotype of bmm heterozy-
gous flies was remarkably similar to that of PGC-1/srl heterozy-
gotes. Thus, bmm1/+ flies accumulated excess fat and consider-
able heart dysfunction on NF, which were further increased by
HFD feeding (Figures 3F–3H). Conversely, systemic bmm over-
expression prevented HFD-induced TAG accumulation (Fig-
ure S3A) and heart dysfunction (Birse et al., 2010). Importantly,
bmm heterozygotes also exhibited heart dysfunction that was
further aggravated by HFD (Figures 3G and 3H). These findings
raised the possibility that ATGL/bmm acts in the same pathway
as PGC-1/srl and TOR in modulating cardiac lipotoxicity.
To test this idea, we first examined bmm expression in TOR7/P
mutant flies. As was observed for PGC-1/srl expression (Figures
3D and S3B), bmm mRNA levels were increased in TOR7/P and
S6KDN flies (Figures 3E and S3C). Conversely, bmm mRNA was
reduced byHFD feeding, and this was reversed in TOR7/Pmutant
flies (Figure 3E), suggesting that bmm acts downstream of TOR
signaling and may be required for the fat-lowering effect of
reduced TOR function. To examine this possibility, we created
double-mutant flies with reduced TOR and bmm function
(TOR7/P;bmm1/+). Compared to the protective effect of TOR7/P
from HFD effects, TOR7/P;bmm1/+ and bmm1/+ mutant flies ex-
hibited similarly increased TAG level and severe degrees of heart
dysfunction on both NF and HFD as wild-type flies on HFD (Fig-
ures 3F–3H), consistent with bmm loss of function compromising
the protection conferred by reduced TOR signaling. These data
therefore suggest that, as with PGC-1/srl, TOR pathway activa-
tion under HFD leads to reduced bmm expression, which in
turn promotes fat accumulation and heart dysfunction (Figure 3I).
Next, we wanted to test whether adult-only manipulation of
bmm or PGC-1/srl was sufficient to mimic (or protect from)
HFD-induced fat accumulation and heart dysfunction. For this
purpose, we used the Gene Switch system (GS) (Osterwalder
et al., 2001; Roman et al., 2001) to conditionally drive—upon
RU-486 addition—gene expression in the adult heart, both
myocardial and pericardial cells (Hand-GS-Gal4; Monnierflies on NF and HFD. Results are expressed as the fold difference in whole-fly
0.01; ***p < 0.001; one-way ANOVA test.
and double-mutant flies displaying heart dysfunction phenotypes, classified as
ostia, narrowed heart regions, and transmission defects).
ined using chi-square test 39% nR 19. WT-NF versus WT-HFD; c2 = 12; p <
us TOR7/P-HFD; c2 = 23.58; p < 0.001. TOR7/P-HFD versus TOR7/P;PGC-1XP/+-
s. TOR7/P; PGC-1XP/+-NF versus TOR7/P; bmm1/+-NF; c2 = 0; ns. TOR7/P;PGC-
7/P; bmm1/+-HFD; c2 = 1.06; ns.
ng, which reduces PGC-1/srl and bmm expression to lead to fat accumulation
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Figure 4. ATGL/bmm Is an Upstream Regu-
lator of PGC-1/srl in HFD-Induced Heart
Dysfunction
(A–F) Relative expression of bmm (A, C, and F) and
PGC-1/srl (B, D, and E) mRNA in bmm KD/over-
expression flies and in PGC-1/srlmutant flies. *p <
0.05; **p < 0.01; Student’s t test. The data are
presented as the mean ± SEM.
(G) Graphical representation of the proportion of
flies with cardiac-specific manipulation of bmm
and PGC-1/srl in a bmm mutant background dis-
playing heart dysfunction phenotypes, classified
as non-contractile regions, asynchronous beating,
and other defects (dysfunctional ostia, narrowed
heart regions, and transmission defects).
(H) Quantification of heart defects shown in (G).
Statistical significance was determined using chi-
square test 19 % n R 14. Hand/+; bmm1/+-NF
versus Hand/UASbmm; bmm1/+-NF; c2 = 10.16;
p < 0.01. Hand/+; bmm1/+-HFD versus Hand/
UASbmm; bmm1/+-HFD; c2 = 10.28; p < 0.01.
Hand/+; bmm1/+-NF versus Hand/PGC-1JW;
bmm1/+-NF; c2 = 7.36; p < 0.01. Hand/+; bmm1/+-
HFD versus Hand/PGC-1JW; bmm1/+-HFD; c2 =
4.96; p < 0.05.Hand/UASbmm; bmm1/+-NF versus
Hand/PGC-1JW; bmm1/+-NF; c2 = 0.05; ns. Hand/
UASbmm; bmm1/+-HFD versus Hand/PGC-1JW;
bmm1/+-HFD; c2 = 1.3; ns.
(I) Schematic of proposed regulatory network.
HFD consumption activates TOR signaling,
which inhibits the expression of bmm and, sub-
sequently, PGC-1/srl in the same axis, leading to
fat accumulation and heart dysfunction. See also
Figure S4.et al., 2012). Administration of ethanol vehicle or RU-486 to wild-
type flies did not noticeably affect ATGL/bmm or PGC-1/srl
expression, fat content, or heart function (Figures S3G–S3K).
However, cardiac KD of ATGL/bmm (Hand-GS > bmmRNAi)
by RU treatment caused an increase in systemic fat content
compared to ethanol vehicle exposure, and conversely, condi-
tional ATGL/bmm or PGC-1/srl overexpression in the adult heart
(Hand-GS > UASbmm or Hand-GS > PGC-1JW) decreased fat
levels (Figure S3D), suggesting metabolic gene manipulation in
cardiac tissue can have a systemic effect (see Grueter et al.,
2012). Importantly, adult-specific overexpression of PGC-1/srl
or ATGL/bmm in the heart of flies treated with RU (Hand-GS >
PGC-1JW and Hand-GS>bmm) showed markedly decreased
heart dysfunction under HFD, compared to ethanol controls (Fig-
ures S3E and S3F). In contrast, Hand-GS > PGC-1RNAi flies1578 Cell Reports 10, 1572–1584, March 10, 2015 ª2015 The Authorstreated with RU exhibited significantly
increased heart dysfunction under NF
and HFD, compared to ethanol controls
(Figures S3E and S3F). These data
demonstrate that PGC-1/srl and ATGL/
bmm manipulation during adult stages
is sufficient to modulate heart function
under NF and HFD. Together with HFD
feeding of adult flies causing increased
TOR signaling (Figure 3A) and decreasedPGC-1/srl and ATGL/bmm expression (Figures 3D and 3E),
these data strongly suggest that PGC-1/srl and ATGL/bmm act
as mediators of HFD-induced heart dysfunction and effectors
of TOR signaling.
To investigate possible genetic interactions between PGC-1/
srl and bmm, we first analyzed PGC-1/srl mRNA levels in bmm
mutant flies. We found that PGC-1/srl RNA levels were signifi-
cantly increased in flies with systemic overexpression of bmm
and significantly reduced in bmm heterozygotes (Figures 4A–
4D). Using the GS system, we found that induced adult heart
expression or KD of ATGL/bmm (Hand-GS > UASbmm-RU or
Hand-GS > BmmRNAi) leads to increased or decreased PGC-1/
srl expression in the heart, respectively (Figures S4A–S4D),
which is consistent with PGC-1/srl acting downstream of
ATGL/bmm in counteracting HFD-induced heart dysfunction.
In PGC-1/srl heterozygous flies, on the other hand, bmm mRNA
levels were similar to wild-type (Figures 4E and 4F). Moreover,
heart-only-induced expression of PGC-1/srl with Hand-GS also
did not significantly alter ATGL/bmm expression (Figures S4E
and S4F). Interestingly, however, hand-GS-induced cardiac
PGC-1/srl KD did exhibit decreased ATGL/bmm levels (Figures
S4G and S4H), suggesting that there may be some feedback
regulation from PGC-1/srl to ATGL/bmm, although ATGL/bmm
acts predominantly upstream PGC-1/srl in modulating HFD-
related cardiac dysfunction (see below and Figures 4G, 4H,
S4I, and S4J).
We next examined the relationship between PGC-1/srl and
ATGL/bmm in regulating heart function. For this purpose, we
examined bmm heterozygous flies with cardiac PGC-1/srl over-
expression (Hand > PGC-1JW;bmm1/+). We found that cardiac
PGC-1/srl overexpression was able to rescue the heart dysfunc-
tion phenotype of bmm heterozygotes under NF and HFD, as
well as a control rescue with ATGL/bmm overexpression (Fig-
ures 4G and 4H). As expected, we also found that cardiac-spe-
cific KD of ATGL/bmm using the myocardial-specific Tin-HE-
Gal4 driver induced a high proportion of heart defects in both
NF- and HFD-fed flies (Figures S4I and S4J). However, concom-
itant cardiac overexpression of PGC-1/srl significantly reduced
the deleterious effects of ATGL/bmm KD (Figures S4I and
S4J). Taken together, these data are consistent with ATGL/
bmm acting upstream of PGC-1/srl in regulating heart function.
These findings suggest that HFD-induced lipid accumulation
and cardiac dysfunction are accompanied by the sequential acti-
vation of TOR, downregulation of ATGL/bmm, and subsequently
PGC-1/srl expression, thus leading to cardiac lipotoxicity
(Figure 4I).
PGC-1/srl and SREBP Likely Act in Parallel to Modulate
HFD-Induced Heart Dysfunction
SREBP is a conserved transcriptional regulator of lipogenic gene
expression (Dobrosotskaya et al., 2002; Osborne and Espen-
shade, 2009; Seegmiller et al., 2002). Activation of SREBP or
its lipogenic targets, including fatty acid synthase (FAS), in-
creases fat accumulation and causes heart dysfunction in
Drosophila (Lim et al., 2011), similar to the effects of reduced
PGC-1/srl function (Figures 1 and 2). To determine the effect of
HFD on processing of full-length (FL) SREBP to the transcription-
ally active mature form (m-SREBP), we created flies carrying a
sensor for m-SREBP-mediated transcriptional activation (Kunte
et al., 2006) together with a UAS-nGFP reporter. In these flies,
activation of m-SREBP is indicated by an increase in GFP fluo-
rescence.We observed that flies fed a HFD showed higher levels
of nuclear GFP in the heart (Figure 5A) and thoracic muscle (Fig-
ure S5A) than NF-fed flies, indicating that SREBP activity was
induced by the HFD. In keeping with this, expression of the
SREBP target gene FASwas also elevated in HFD-fed compared
to NF-fed flies (Figure 5E).
Interestingly, FAS expression was also increased in PGC-1/srl
heterozygotes compared to wild-type flies on both NF and HFD
(Figure 5E). Also, bmm overexpression and mutant flies have
decreased and increased FAS levels, respectively (Figures S5B
and S5C). Therefore, we asked whether SREBP and PGC-1/srl
interacted to induce fat accumulation and heart dysfunction inCellresponse to the HFD. For this purpose, processing of FL-SREBP
to m-SREBP was analyzed by western blot analysis. Wild-type
flies fed a HFD showed increased levels of both FL-SREBP
and m-SREBP compared with flies on NF (Figures 5B–5D); how-
ever, SREBP expression in PGC-1/srl heterozygotes, which
contain similar levels of TAG on NF as do wild-type flies on
HFD, was not significantly different from wild-type flies in either
NF or HFD conditions (Figures 5B–5D). Similarly, SREBP hetero-
zygotes expressed reduced levels of FAS mRNA (Figure 5F),
but not of PGC-1/srl mRNA (Figure 5G). Therefore, these data
suggest that PGC-1/srl and SREBP do not affect each other’s
expression in their modulation of fat accumulation and may
occur through distinct mechanisms.
Finally, we examined directly the relationship between SREBP
and PGC-1/srl in modulating heart function. Cardiac dysfunction
was slightly less prevalent inHFD-fedSREBPheterozygotes than
in wild-type flies (Figures 5H and 5I), suggesting that SREBP
partially mediates the deleterious effect of HFD on the heart.
SREBP and PGC-1/srl double-heterozygous flies exposed to a
HFDshowedaheart phenotype strikingly similar to that ofSREBP
heterozygotes (Figures 5H and 5I). In addition, we found that
PGC-1/srl and FAS double KD in the heart produced only a slight
reduction of heart dysfunction compared to PGC-1/srl single KD
(Figures S5D and S5E), which would be consistent with SREBP
being the dominant regulator of FAS in the heart (see Lim et al.,
2011) and PGC-1/srl also acting through other effectors. Overall,
the data suggest that SREBPmay at least in part act in parallel to
PGC-1/srl, but it cannot be ruled out that PGC-1/srl also acts
downstream (or vice versa), through FAS and possibly other
effectors, in regulating heart function (illustrated in Figure 6).
Collectively, these findings are consistent with a model in which
SREBP and Bmm-PGC-1/Srl function downstream of TOR and
in parallel to each other, interconnected via FAS, to control fat
accumulation and heart function. In conclusion, we found that
HFD causes excess fat accumulation and cardiac dysfunction
via TOR-dependent activation of two parallel pathways: TOR-
ATGL/Bmm-PGC-1/Srl and TOR-SREBP (Figure 6).
DISCUSSION
It is well established that lipid accumulation in cardiomyocytes
can lead to cardiac dysfunction (e.g., Zhang and Ren, 2011),
but the genetic and metabolic regulatory networks that mediate
cardiac lipotoxicity have yet to be fully understood. Here, we
used the Drosophila model to investigate the genetic relation-
ships between PGC-1/srl and other metabolic regulators to
elucidate the mechanisms of HFD-induced obesity and cardiac
dysfunction. We found that reducing PGC-1/srl function was suf-
ficient to induce TAG accumulation and cardiac lipotoxicity, a
phenotype remarkably similar to that observed in wild-type,
HFD-fed flies. Indeed, HFD feeding reduced PGC-1/srl expres-
sionwild-type flies. Conversely,PGC-1/srl overexpression coun-
tered both the fat accumulation and associated heart defects
induced by HFD, indicating that PGC-1/srl is both necessary
and sufficient for counteracting obesity and associated cardiac
lipotoxicity. In humans, genome-wide association studies con-
ducted with various ethnic and geographical cohorts have sug-
gested a possible link between obesity and variants in PGC-1Reports 10, 1572–1584, March 10, 2015 ª2015 The Authors 1579
Figure 5. SREBP and PGC-1/srl Function
through Parallel Pathways in HFD-Induced
Heart Dysfunction
(A) Representative micrographs of sections of
hearts of flies carrying a UAS-GFP/SREBP sensor
and fed NF (top) or HFD (bottom). Sections were
stained with anti-GFP antibody (green). Arrow-
heads indicate increased GFP staining (SREBP
activation) in the nuclei of hearts from HFD-fed
flies.
(B–D) Western blots of SREBP (FL, full-length; m,
mature isoform) in whole-fly extracts of WT and
PGC-1XP/+ flies on NF or HFD (A). Actin was
included as a loading control. (C) and (D) are
quantification of relative FL SREBP protein (C) and
m-SREBP from westerns in (B) (D). Kruskal-Wallis
test was used for the statistics. **p < 0.01. The
data are presented as the mean ± SEM.
(E) Relative expression of FAS mRNA in WT and
PGC-1XP/+ flies on NF or HFD. Results are mean ±
SD of n = 30; *p < 0.05; **p < 0.01; one-way
ANOVA test.
(F and G) Relative expression of (F) FAS and (G)
PGC-1/srl mRNA in WT and SREBP mutant flies
on NF or HFD. Results are mean ± SD of n = 30;
*p < 0.05; one-way ANOVA test.
(H) Graphical representation of the proportion
of SREBP and PGC-1/srl mutant flies displaying
heart dysfunction phenotypes, classified as
non-contractile regions, asynchronous beating,
and other defects (dysfunctional ostia, narrowed
heart regions, and transmission defects).
(I) Quantification of heart defects shown in (H).
Statistical significance was determined using chi-
square test 26% nR 14. WT-NF versus WT-HFD;
c2 = 12; p < 0.001. PGC-1XP/+-NF versus
SREBP52/+-NF; c2 = 0.3; ns. PGC-1XP/+-HFD
versus SREBP52/+-HFD; c2 = 3; ns. SREBP52/+-NF
versus SREBP52/PGC-1 XP-NF; c2 = 1.5; ns.
SREBP52/+-HFD versus SREBP52/PGC-1XP-HFD;
c2 = 0.01; ns. See also Figure S5.genes (Muller et al., 2003; Arya et al., 2004). Moreover, reduced
PGC-1 gene expression was observed in patients with diabetes
and those developing insulin resistance, but no clear mechanism
of action has been established (Mootha et al., 2003; Patti et al.,
2003). In mammals, PGC-1 genes are known to control cardiac
metabolism and function (Schilling and Kelly, 2011; Lai et al.,
2008; Russell et al., 2004; Rowe et al., 2010), and reduced
PGC-1a has been linked to heart failure and hypertrophy in ro-
dent models of heart disease (Lehman and Kelly, 2002; Arany
et al., 2006; Huss and Kelly, 2005). Thus, our demonstration of
a close association between PGC-1/srl function, excess fat
accumulation, and cardiac lipotoxicity further supports a critical
role for this coactivator in diabetic cardiomyopathy. In addition,
we demonstrate for the first time that reduction PGC-1/srl func-
tion is essential in mediating HFD-induced heart dysfunction.1580 Cell Reports 10, 1572–1584, March 10, 2015 ª2015 The AuthorsWedemonstrated that HFD feeding ac-
tivates TOR signaling (increased P-AKT
and P-S6K), which in turn leads to down-
regulation of PGC-1/srl expression. Incontrast, a reduction in TOR function, which protects against
obesity and heart dysfunction, is associated with increased
PGC-1/srl levels. Furthermore, reducing both PGC-1/srl and
TOR function (TOR7/P;PGC-1xp/+) abrogated the protective ef-
fects of TOR reduction against HFD-induced obesity and heart
dysfunction. These findings therefore suggest that PGC-1/srl is
a negative downstream effector of TOR. We suggest that persis-
tent activation of TOR in response to a HFD reduces PGC-1/srl
expression, which in turn leads to lipid accumulation in the
myocardium and provokes heart dysfunction.
We also identified ATGL/Bmm lipase as a downstream
effector of TOR in HFD-induced obesity and heart dysfunction,
and the effects of a HFD were similar in bmm and PGC-1/srl
mutant flies. Importantly, bmm RNA levels were increased in
TOR mutant flies and—as observed with PGC-1/srl—reduction
Figure 6. Model of Genetic Network in HFD-Induced Cardiac Lip-
otoxicity
HFD feeding causes increased TOR signaling that leads to decreased
PGC-1/srl expression via decreased ATGL/bmm function mediating obesity
and cardiac lipotoxicity. There may be some feedback from PGC-1/srl to
ATGL/bmm in the heart itself, but in regards to modulation of HFD-depen-
dent heart dysfunction PGC-1/srl acts downstream of ATGL/bmm. SREBP is
also activated by TOR and is interconnected to the ATGL/bmm-PGC-1/srl
axis via FAS to contribute to the regulation of HFD-inflicted cardiac lip-
otoxicity.of bmm function in TOR mutant flies (TOR7/P;bmm/+) eliminated
the beneficial effects of TOR. Becausemodulation of bmm domi-
nantly induced changes in PGC-1/srl mRNA levels and cardiac-
specific increase in PGC-1/srl levels in bmm KD flies protected
against heart dysfunction, we conclude that PGC-1/srl acts
downstream of bmm and TOR, thus delineating a genetic
pathway from TOR to PGC-1/srl via ATGL/bmm.CellInterestingly, a recent study showed that mammalian ATGL
controls murine heart dysfunction via PPARs (Haemmerle
et al., 2011). Here, we demonstrated that this relationship also
appears to exist in the fly and, importantly, provides strong evi-
dence that, under HFD conditions, ATGL/bmm and PGC-1/srl
act downstream of TOR in mediating cardiac lipotoxicity. Inter-
estingly, in the above study, cardiac PGC-1 gene expression is
also reported to be reduced with ATGL deficiency (Haemmerle
et al., 2011), thus placing PGC-1 gene function downstream of
ATGL in both the fly and the mouse heart. Although molecules
of equivalent function to mammalian PPARs have not yet been
conclusively identified in Drosophila, our findings are consistent
with the presence of a fundamentally conserved epistatic rela-
tionship between TOR, bmm, and PGC-1/srl in the metabolic
control of cardiac lipotoxicity.
Previous studies have suggested that TOR stimulates lipogen-
esis via a SREBP-dependent increase in FAS expression (Porst-
mann et al., 2008; Hagiwara et al., 2012), and we have recently
shown that SREBP lipogenic activity strongly influences heart
function in Drosophila (Lim et al., 2011). In this study, we demon-
strate that, under HFD conditions, PGC-1/Srl and SREBP do not
seem to directly regulate each other and may act independently
to regulate fat accumulation and heart function, which implies
that HFD activation of TOR signaling triggers parallel but partially
interdependent pathways to regulate lipogenesis (through FAS).
This does not preclude that PGC-1/srl and SREBP (as well as
bmm) also have FAS-unrelated functions in modulating fat accu-
mulation and cardiac function. In our model, we propose that
HFD activation of the nutrient-sensing TOR pathway leads to
downregulation of the bmm-PGC-1/srl axis and to upregulation
of the SREBP axis, both resulting, at least in part, in FAS upregu-
lation. Such a mechanism would have two deleterious conse-
quences: increased circulating fat levels and increased storage
of fat in non-adipose tissues, leading to lipotoxicity and cardiac
dysfunction. Interestingly, rodent models of obesity also show
increased TAG deposition in the heart and subsequent develop-
ment of cardiac lipotoxicity (Borradaile and Schaffer, 2005; Zhou
et al., 2000; Christoffersen et al., 2003). These findings suggest
that HFD feeding perturbs homeostatic pathways that are tightly
regulated when fat intake is normal.
In humans, type 2 diabetes and associated diseases of the
metabolic syndrome are aggravated with age. A recent study
in Drosophila by Rera et al. (2011) has shown that PGC-1/srl
expression decreases with age in the intestine and PGC-1/srl
overexpression was sufficient to delay tissue aging, at least in
part by increasing mitochondrial activity. These data are consis-
tent with our findings that PGC-1/srl overexpression protects
against obesity and cardiac dysfunction. Further studies will be
required to determine our proposed network of gene regulation
is also operational with regards to PGC-1/srl’s role in cardiac
and overall aging. Conversely, it will be of interest to determine
whether increasing certain aspects of mitochondrial function in
the heart is sufficient to counteract the cardiac lipotoxicity of
HFD feeding.
In a recent report, TORsignalingwas found to functionasapos-
itive regulator of PGC-1/srl in growth process during larval devel-
opment of Drosophila (Mukherjee and Duttaroy, 2013), which
is consistent with previous findings that PGC-1/srl-deficientReports 10, 1572–1584, March 10, 2015 ª2015 The Authors 1581
Drosophila larvae exhibit dramatic growth impairment (Tiefen-
bo¨ck et al., 2010). In contrast, however, we provided strong evi-
dence in this study that, duringmetabolic homeostasis in theadult
animal, PGC-1/srl is a negative effector of HFD-induced augmen-
tation of TOR signaling. Thus, during organismal and tissue
growth, PGC-1/srl mediates TOR signaling. But in the adult
upon a metabolic or dietary insult, activation of TOR function
and downstream ATGL/bmm lipase inhibition prevents PGC-1/
srl function, establishing a new genetic relationship between
TOR and PGC-1/srl.
In this study, we have identified an integrated genetic network
of metabolic regulators in the control cardiac lipotoxicity, in
particular, PGC-1/srl acting as a negative effector of TOR. The
network connects insulin-TOR, ATGL/Bmm, PGC-1/Srl, SREBP,
and FAS, all of which have been associated with obesity in hu-
mans (Rankinen et al., 2006; Yang et al., 2007), but their relation-
ships have not been comprehensively elucidated. Our work thus
identifies a prototypical gene network with significant relevance
for understanding lipotoxic cardiomyopathy in humans and
further emphasizes the utility of theDrosophila heart model in un-
raveling complex metabolic processes in higher organisms.
EXPERIMENTAL PROCEDURES
HFD Feeding Regimen
Flies were aged for 5 days after eclosion in tubes (25 flies/tube) containing NF
and then transferred to NF or HFD (NF + 30% coconut oil) for 5 days, as pre-
viously described (Birse et al., 2010). Identical groups of flies were either
weighed and frozen at 80C for determination of TAG content (Birse et al.,
2010) or analyzed for heart function abnormalities (see below).
Semi-intact Drosophila Heart Preparation and Digital High-Speed
Movie Analysis
All dissection steps were performed in artificial hemolymph saline, as previ-
ously described (Ocorr et al., 2007). Flies were anesthetized with FlyNap (Car-
olina Biochem) and transferred to a Vaseline-coated Petri dish for dissection as
described (Vogler and Ocorr, 2009). The submerged dissected hearts were
oxygenated for 15 min at room temperature to equilibrate. High-speed digital
movies were made with a Leica DM-LFSA microscope with a 103 water im-
mersion lens, a Hamamatsu EM-CCD camera, and HCI image capture soft-
ware (Hamamatsu). Movies were analyzed with custom-designed software
(Fink et al., 2009; Ocorr et al., 2007). See also the Supplemental Experimental
Procedures and references.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and seven movies and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.02.022.
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